Oct, 25 2011-
Intrexon Acquires Immunologix, Inc.
Novel Fully Human Antibody Development Group Joins Top Synthetic Biology Company
BLACKSBURG, VA, Oct 24, 2011 (MARKETWIRE via COMTEX) -- Intrexon Corporation, a privately held synthetic biology company, today announced the acquisition of Immunologix, Inc., of Charleston, SC. Immunologix specializes in transforming naive B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Terms of the transaction were not disclosed.